Unknown PHASE4 INTERVENTIONAL 2-arm NCT03855826

Evaluation of the Efficacy and Safety of Nifekalant Hydrochloride (NIF) Injection.

Evaluation of the Efficacy and Safety of Nifekalant Hydrochloride (NIF) Injection in the Treatment of Ventricular Tachycardia and Ventricular Fibrillation. A Multicenter, Randomized, Controlled, Open-label, Clinical Trial.

Sponsor: Sichuan Baili Pharmaceutical Co., Ltd.

Conditions Ventricular Fibrillation Ventricular Tachycardia

Interventions Amiodarone Nifekalant hydrochloride

Updated 5 times since 2019 Last updated: Feb 25, 2019 Started: Jan 15, 2019 Primary completion: Jan 30, 2020 Completion: Jan 30, 2020

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE4 clinical study on Ventricular Fibrillation and Ventricular Tachycardia, this trial is ongoing. The trial is conducted by Sichuan Baili Pharmaceutical Co., Ltd. and has accumulated 5 data snapshots since 2019. Cardiovascular trials of this type often inform treatment guidelines for long-term patient management.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Unknown PHASE4
Jul 2024 — Sep 2024 [monthly]

Unknown PHASE4

Status: Unknown Status → Unknown
Oct 2021 — Jul 2024 [monthly]

Unknown Status PHASE4

Status: Recruiting → Unknown Status
Jan 2021 — Oct 2021 [monthly]

Recruiting PHASE4
Mar 2019 — Jan 2021 [monthly]

Recruiting PHASE4

First recorded

Jan 2019

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Sichuan Baili Pharmaceutical Co., Ltd.

Data source: Sichuan Baili Pharmaceutical Co., Ltd.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Shenyang, China